European Medicines Agency Validates Bristol Myers Squibb's Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy Biotech Investing
Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study Pharmaceutical Investing
InvestmentPitch Media Video Discusses Love Pharma, a New Listing on the CSE, Focused on the Global Sexual Health, Wellness, and Psychedelics Markets - Video Available on Investmentpitch.com Pharmaceutical Investing
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma Biotech Investing
Abbott Commits to Reducing Malnutrition Globally with Launch of Abbott Center for Malnutrition Solutions Medical Device Investing
AbbVie Presents Late-Breaking Data on Risankizumab in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology Congress Biotech Investing
Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases Biotech Investing
AbbVie Presents New Analyses Evaluating RINVOQ® in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress Biotech Investing
Love Pharma, Inc., Formerly Glenbriar Technologies, Inc., Announces Name Change, Consolidation, and Acquisition of Kick Pharmaceuticals, Inc Pharmaceutical Investing
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 in Dry Eye Disease Associated with Meibomian Gland Dysfunction Medical Device Investing
